• 文献标题:   Binary transition metal oxide modified laser-scribed graphene electrochemical aptasensor for the accurate and sensitive screening of acute myocardial infarction
  • 文献类型:   Article
  • 作  者:   RAUF S, MANI V, LAHCEN AA, YUVARAJA S, BEDUK T, SALAMA KN
  • 作者关键词:   laserscribed graphene, electrochemical aptasensor, cardiac troponini ctni, binary transition metal oxide, acute myocardial infarction, disease biomarker
  • 出版物名称:   ELECTROCHIMICA ACTA
  • ISSN:   0013-4686 EI 1873-3859
  • 通讯作者地址:  
  • 被引频次:   17
  • DOI:   10.1016/j.electacta.2021.138489 EA MAY 2021
  • 出版年:   2021

▎ 摘  要

Laser-scribed graphene (LSG) electrodes have gained significant interest due to the ease in fabrication, surface modification, and potential to develop various types of electrochemical sensors and biosensors. In these studies, a new type of zinc ferrite nanoparticles (ZnFe2O4 NPs) modified LSG electrochemical sensing system comprising LSG-ZnFe2O4 working electrode, LSG reference, and LSG counter electrode on a single polyimide substrate is presented. LSG-ZnFe2O4 electrodes are fabricated by drop-casting a solution of ZnFe2O4 NPs onto the LSG electrode, which gave a 31% enhancement of sensitivity and electrocatalytic activity compared to the bare LSG electrode. LSG-ZnFe2O4 electrochemical aptasensor for acute myocardial infarction (AMI) screening is developed by detecting the cardiac Troponin-I (cTn-I) biomarker. The results show that the developed aptasensor could detect a broad concentration range of cTn-I with a limit of detection of 0.001 ng/mL and a sensitivity of 19.32 (+/- 0.25) mu A/(ng/mL). In addition to this, LSG-ZnFe2O4-aptasensor shows higher selectivity towards the detection of cTn-I and negligible cross-reactivity with other interfering biomolecules. Finally, it is demonstrated that LSG-ZnFe2O4-aptasensor can easily detect different concentrations of cTn-I spiked in human serum samples. These results show that the LSG-ZnFe2O4-aptasensor is a promising diagnostic tool to monitor cTn-I and could be a potential candidate to develop point-of-care devices for cTn-I biomarker detection and various other disease biomarkers in the future. (C) 2021 Elsevier Ltd. All rights reserved.